I noted this in the Trial Updates Recce Pharmaceuticals (RCE) expects more data to be released in the coming months from several clinical studies of its anti-infectivesThe company says first patient dosing will get underway in August for its Intravenous (I.V.) Phase I Human Clinical Trial, which is set to run for one yearBy Q4 2021, RCE expects data to begin arriving from its Topical Phase I/II Human Burns Study, with the eight-month trial recently getting underway in WAAround the same time, Recce says it should also begin receiving data from its SARS-CoV-2 (COVID-19) International Studies despite a recent delay
RCE Price at posting:
83.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)